BLA 125249 · Kiniksa Pharmaceuticals (Uk), Ltd.
Arcalyst
Rilonacept · Single-Use
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Feb 27, 2008
Approved uses
3
Original approval plus efficacy supplements
Registered trials
26
7 Phase 3, 1 recruiting
FAERS reports
1,157
284 serious, 26 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2025.
ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) 1.1 Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome ARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and pediatric patients 12 years and older. 1.2 Deficiency of IL-1 Receptor Antagonist ARCALYST is indicated for the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg. 1.3 Recurrent Pericarditis ARCALYST is indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
Mechanism: Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist (IL-1ra). The equilibrium dissociation constants for rilonacept binding to IL-1α, IL-1β, and IL-1ra were 1.4 pM, 0.5 pM, and 6.1 pM, respectively. CAPS refers to rare genetic syndromes generally caused by mutations in the NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 18, 2021 Supplement 49 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Dec 18, 2020 Supplement 47 · Efficacy · priority review OrphanLabelLetter
- Feb 27, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- ARCALYST · RILONACEPT 220MG · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rilonacept" as an intervention, any sponsor and status, largest first.
- Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00856206 · 1,315 participants · Start Mar 2009 · Primary completion Jan 2011
Drug: Rilonacept · For: Gout
Sites: Alabaster, Alabama; Mesa, Arizona; Burbank, California · 124 sites in all
- PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00958438 · 248 participants · Start Jul 2009 · Primary completion Dec 2010
Drug: Placebo; Rilonacept and 1 more · For: Gout
Sites: Berlin, Germany; Essen, Germany; Goch, Germany · 61 sites in all
- PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00829829 · 241 participants · Start Feb 2009 · Primary completion May 2010
Drug: Rilonacept 80 mg; Rilonacept 160 mg · For: Intercritical Gout
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 91 sites in all
- Study Utilizing Rilonacept in Gout ExacerbationsPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00855920 · 225 participants · Start Mar 2009 · Primary completion Feb 2010
Drug: Rilonacept; Indomethacin · For: Acute Gout Flare
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 44 sites in all
- Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout FlaresPivotal-lookingTerminated
Regeneron PharmaceuticalsRegeneron (REGN)
NCT01459796 · 220 participants · Start Nov 2011 · Primary completion Jun 2013
Drug: Rilonacept; Placebo and 1 more · For: Gout
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 74 sites in all
- Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00288704 · 104 participants · Start Dec 2005 · Primary completion Jun 2008
Drug: rilonacept 160 mg; Placebo and 1 more · For: Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS) and 1 more
Sites: Little Rock, Arkansas; Palm Desert, California; Upland, California · 24 sites in all
- Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent PericarditisPivotal-lookingCompleted
Kiniksa Pharmaceuticals (UK), Ltd.Industry
NCT03737110 · 86 participants · Start Jan 7, 2019 · Primary completion May 29, 2020
Drug: Rilonacept; Placebo · For: Recurrent Pericarditis
Sites: Los Angeles, California; Atlanta, Georgia; Chicago, Illinois · 21 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00610363 · 83 participants · Start Nov 2007 · Primary completion Oct 2008
Drug: Rilonacept · For: Gout
Sites: San Diego, California; Santa Maria, California; Whittier, California · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site erythema134
- chest pain120
- product dose omission issue103
- pericarditis90
- fatigue89
- injection site pain88
- off label use85
- drug ineffective76
- pain76
- injection site pruritus68
- injection site rash67
- dyspnoea63
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 10 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 14 |
| 2017 | 9 |
| 2018 | 21 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 15 |
| 2022 | 170 |
| 2023 | 73 |
| 2024 | 190 |
| 2025 | 399 |
| 2026 | 219 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arcalyst (Rilonacept)
2024 spending
$53.2M
Beneficiaries
358
2,303 claims
Per beneficiary
$148,573
$5,654.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $3,659,618 |
| 2022 | $11,710,170 |
| 2023 | $24,779,791 |
| 2024 | $53,189,124 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL, Imazio M, Cremer P, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O · Front Immunol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.
Kilic B, Ozturk A, Karup S, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Network Meta-Analysis
- Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.
Schlesinger N, Pillinger MH, Simon LS, et al. · Arthritis Res Ther 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
Brucato A, Wheeler A, Luis SA, et al. · Heart 2023 · Randomized Controlled Trial, Multicenter Study
- Interleukin-1 inhibitors for acute gout.
Sivera F, Wechalekar MD, Andrés M, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Kiniksa Pharmaceuticals (Uk), Ltd.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.